Straumann
 | |
| Type | Public |
|---|---|
| Industry | Pharmaceutics |
| Founded | 1954 |
| Headquarters | Basel, Switzerland |
| Key people |
Gilbert Achermann (Chairman) Marco Gadola (CEO) |
| Products | Dental implants |
| Employees | 2300 (01.07.2013) |
| Website | www.straumann.com |
Headquartered in Basel, Switzerland, the Straumann Group (SIX: STMN) acts in implant and restorative dentistry and oral tissue regeneration.
Recently, Straumann entered the fast-growing field of restorative dentistry through the acquisition of etkon, an emerging force in CAD/CAM based tooth replacement. Straumann offers surgical, restorative and regenerative solutions - from bone augmentation and tissue regeneration, through implants and prosthetics, to individualized crowns and bridges.
In collaboration with leading clinics, research institutes and universities, Straumann research and develop implants, instruments and tissue regeneration products for use in tooth replacement solutions or to prevent tooth loss.
The Group manufactures implant system components and instruments in Switzerland and the US and dental tissue regeneration products in Sweden. The restorative products are manufactured in Europe and the US.
Straumann also offer comprehensive training and services to the dental profession worldwide, including training and education, which is provided in collaboration with the International Team for Implantology (ITI).
Altogether, Straumann employs approximately 2300 people worldwide and their products and services are available in more than 70 countries through their own distribution subsidiaries and broad network of distribution partners.
History
The history of the Straumann Group has three distinct eras and spans more than half a century. It began in the Swiss village of Waldenburg in 1954 with the foundation of a research institute bearing the name of its founder, Dr Ing. Reinhardt Straumann.
1954–1970
Between 1954 and 1970, the company specialized in alloys used in timing instruments and in materials testing. Among Straumann’s renowned inventions in this period were special alloys that are still used in watch springs today. A breakthrough in the use of non-corroding alloys for treating bone fractures prompted Dr Fritz Straumann to enter the fields of orthopedics and dental implantology, which began the second phase of the company’s history.
1954
In the small town of Waldenburg, at the foot of the Swiss Jura, Reinhard Straumann founds the "Dr Ing. R. Straumann Research Institute AG".
1960
The Swiss Association for the Study of Internal Fixation (AO/ASIF) is looking for a company that is capable of providing materials for internal fixation implants - Dr H.C. Fritz Straumann, son of the company’s founder, gets in touch.
1970–1990
Between 1970 and 1990, Straumann became a leading manufacturer of osteosynthesis implants. A management buy-out of the osteosynthesis division in 1990 led to the creation of Stratec (subsequently Synthes) as a separate company. 1990 thus marked the beginning of the Straumann Group as it is known today. Thomas Straumann, grandson of the founder, headed the remaining part of the firm, which employed just 25 people focused exclusively on dental implants.
Another major milestone in the company’s history was in 1980 when Straumann established a partnership with the International Team for Implantology forming a symbiosis of research expertise and industrial know-how. The 1980s also marked the company’s geographic expansion, with subsidiaries in Germany (1980) and the US (1989). The following are examples of the groundbreaking achievements that have established Straumann as a leading innovator in implant dentistry:
1974
The first dental implants are developed at the Institut Straumann and undergo successful clinical testing at the University of Berne.
1980
Under the aegis of Dr Fritz Straumann, Waldenburg, and Prof Schroeder, University of Berne, the International Team for Implantology, the ITI, is founded.
1990
After a management buy-out of the internal fixation division, Thomas Straumann focuses the activities of the Institut Straumann AG on the area of implant dentistry.
1998 - Today
In 1998, Straumann Holding AG became a publicly traded company on the Swiss exchange. Through the acquisition of Kuros Therapeutics (2002) and Biora (2003), Straumann entered the promising field of oral tissue regeneration.
1998
The Straumann Holding AG goes public and is listed on the Swiss stock exchange.
2000
With the opening of the production site in Villeret, located in the Berne Jura, and the Technology Center in Waldenburg, new dimensions open up for the international Straumann group.
2002
Straumann acquires Kuros Therapeutics AG and extends its activities into the field of biomaterials.
2003
Straumann acquires the Swedish company Biora, a pioneer in the area of biologically based regeneration of dental tissue. The main product Emdogain has considerable advantages compared to conventional products because of its ease of use. Emdogain is thus a further important element in Straumann‘s very promising future in the area of oral tissue regeneration.
'2004
Straumann AG moves into its new headquarters in Basel.
Organization
Board of Directors
- Gilbert Achermann - Chairman of the Board
- Dr. H.C. Thomas Straumann - Vice Chairman of the Board, Member Strategy Committee
- Dr. Sebastian Burckhardt - Member Audit Committee, Secretary of the Board
- Dominik Ellenrieder - Member Strategy Committee
- Roland Hess - Chair Audit Committee, Member Strategy Committee
- Ulrich Looser - Chair Strategy Committee, Member HR Committee
- Dr. Beat Lüthi - Member Audit Committee, Member HR Committee
- Stefan Meister - Chair HR Committee
Executive Management Board
- Marco Gadola - President and Chief Executive Officer
- Thomas Dressendörfer - Chief Financial Officer
- Wolfgang Becker - Head Sales Central Europe
- Guillaume Daniellot - Executive Vice President Sales Western Europe
- Andy Molnar - Head Sales North America
- Dr. Alexander Ochsner - Head Sales APAC
- Frank Hemm - Head Customer Solutions & Marketing
- Dr. Sandro Matter - Head Strategic Projects & Alliances
- Dr. Gerhard Bauer - Head Research, Development & Operations
Production
Straumann is the only leading company in its industry that offers surgical, restorative and regenerative solutions from bone to crown. The product range includes surgical implants and prosthetic components (abutments) that connect the implant with the visible crown of the replacement tooth. Straumann also supply a range of matching precision instruments and handling components.
Every item in Straumann’s Dental Implant System is crafted to the highest quality standards, ensuring long-term safety and reliability. Straumann provide a CAD/CAM based service for producing highly esthetic tooth restorations ranging from single inlays and crowns to 14-unit bridges in a selection of materials including high-tech ceramics.
Complementing the dental implant and restoration system Straumann manufacture products that are used in oral tissue regeneration either to support implant procedures or to help preserve teeth after treatment for periodontal disease.
The Group manufactures implant system components and instruments in Villeret (Switzerland) and Andover (USA), and dental tissue regeneration products in Malmö (Sweden). The tooth restoration products are produced in Europe and the US.
Villeret
All major components of the Straumann Dental Implant System are currently manufactured at Straumann's state-of-the-art factory in Villeret, Switzerland, which produces more than 4.5 million parts a year.
Villeret became operational in 2000. Continued global volume growth made it necessary to expand capacity, and a second production floor was fitted out in 2005. As a result, Villeret now operates two fully independent production lines, one producing surgical products (implants) and the other manufacturing components for the range of implant prosthetics (abutments). Villeret also houses the manufacturing unit for Straumann's third generation implant surface technology SLActive.
Andover
The North American headquarters in Andover house Straumann’s first manufacturing unit outside Switzerland and produces implant system components and instruments.
The 7,400-square-meter (80,000-square-foot) production area complements Straumann’s current production unit in Villeret, Switzerland. The new unit is being set up according to the rigorous quality requirements of the Villeret facility to guarantee Straumann Swiss precision - made in the USA.
Malmö
In contrast to Villeret and Andover, Straumann's production unit in Malmö is devoted primarily to the specialized manufacture of regenerative products.
In June 2003 Straumann acquired the Swedish company Biora, which specialized in the manufacture of the protein-based products for tissue regeneration. The manufacture of Emdogain, an easy to apply protein based gel for use in periodontal disease, is focused in Malmö.